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Abstract
Following the emergence and global spread of a novel H1N1 influenza virus in 2009, two A(H1N1)pdm/09 influenza
vaccines produced from the A/California/07/09 H1N1 strain were selected and used for the national immunisation
programme in the United Kingdom: an adjuvanted split virion vaccine and a non-adjuvanted whole virion vaccine. In this
study, we assessed the immune responses generated in inbred large white pigs (Babraham line) following vaccination with
these vaccines and after challenge with A(H1N1)pdm/09 virus three months post-vaccination. Both vaccines elicited strong
antibody responses, which included high levels of influenza-specific IgG1 and haemagglutination inhibition titres to H1
virus. Immunisation with the adjuvanted split vaccine induced significantly higher interferon gamma production, increased
frequency of interferon gamma-producing cells and proliferation of CD42CD8+ (cytotoxic) and CD4+CD8+ (helper) T cells,
after in vitro re-stimulation. Despite significant differences in the magnitude and breadth of immune responses in the two
vaccinated and mock treated groups, similar quantities of viral RNA were detected from the nasal cavity in all pigs after live
virus challenge. The present study provides support for the use of the pig as a valid experimental model for influenza
infections in humans, including the assessment of protective efficacy of therapeutic interventions.
Citation: Lefevre EA, Carr BV, Inman CF, Prentice H, Brown IH, et al. (2012) Immune Responses in Pigs Vaccinated with Adjuvanted and Non-Adjuvanted
A(H1N1)pdm/09 Influenza Vaccines Used in Human Immunization Programmes. PLoS ONE 7(3): e32400. doi:10.1371/journal.pone.0032400
Editor: Yi Guan, The University of Hong Kong, China
Received December 8, 2011; Accepted January 30, 2012; Published March 9, 2012
Copyright:  2012 Lefevre et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The present study was conducted within the remit of the COmbating Swine Influenza (COSI) consortium, funded by the Biotechnology and Biological
Sciences Research Council (BBSRC), Medical Research Council (MRC), Department for Environment, Food and Rural Affairs (Defra) and Wellcome Trust (BB/
H014292/1). Additional financial support for this research was also provided by the Institute for Animal Health. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: eric.lefevre@iah.ac.uk
" Membership of COSI is provided in the Acknowledgments.
Introduction
In June 2009, the World Health Organization (WHO) declared
an H1N1 influenza pandemic in response to the emergence and
global spread of a novel H1N1 influenza A virus - A(H1N1)pdm/
09 (http://www.who.int/mediacentre/news/statements/2009/
h1n1_pandemic_phase6_20090611/en/index.html), which con-
tained a unique combination of gene segments derived from
multiple viruses that have been circulating in pigs for decades [1].
Most A(H1N1)pdm/09 cases in humans resulted in mild illnesses,
but in some people, more serious symptoms and fatalities have
been reported [2].
In the UK, two A(H1N1)pdm/09 influenza vaccines produced
from the A/California/07/09 H1N1 strain (Cal07) were used for
the national immunisation programme: (i) Pandemrix (Glaxo-
SmithKline Biologicals S.A., GSK), an AS03b-adjuvanted split
virion vaccine derived from embryonated chicken eggs, adminis-
tered once in healthy adults, and (ii) Celvapan (Baxter AG), a non-
adjuvanted whole virion vaccine derived from Vero cell culture,
administered twice with a minimum of 3 weeks between injections.
These A(H1N1)pdm/09 vaccines were authorized under ‘‘Excep-
tional Circumstances’’ on the basis of limited to very limited safety
and immunogenicity data obtained with these A(H1N1)pdm/09
influenza vaccines and also utilised more complete safety and
immunogenicity data obtained with H5N1 ‘‘mock-up’’ vaccines -
e.g. similar versions of the A(H1N1)pdm/09 vaccines that contain
the whole H5N1 A/Vietnam/1203/2004 influenza virus for the
non-adjuvanted whole vaccine or the viral surface protein
haemagglutinin (HA) derived from H5N1 A/Vietnam/1194/
2004 for the adjuvanted split vaccine (product characteristics
described in http://www.ema.europa.eu/docs/en_GB/documen-
t_library/Other/2010/01/WC500059182.pdf and http://www.
dossiers-sos-justice.com/media/00/01/1744671157.pdf, respec-
tively). For both vaccines, the immunogenicity data at the time
of authorization was based on the generation of anti-HA
antibodies following vaccination with either the A(H1N1)pdm/
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09 and/or ‘‘mock-up’’ vaccines, and included some antigenic
cross-reactivity data. For the adjuvanted split vaccine, non-clinical
studies were solely based on results obtained following the
vaccination and challenge of ferrets with the ‘‘mock-up’’ vaccine.
For the non-adjuvanted whole vaccine, two non-clinical studies
were performed in ferrets vaccinated with the ‘‘mock-up’’ vaccine
and one study was performed in mice using the A(H1N1)pdm/09
vaccine. Regarding the latter study, Kistner et al. recently reported
that the non-adjuvanted whole vaccine provided protection
against challenge with Cal07 with respect to undetectable virus
titers in the lung tissue of vaccinated CD1 mice [3]. Since these
A(H1N1)pdm/09 vaccines were made available, several authors
have reported that both were strongly immunogenic in adults
and/or children [4,5].
The generation of neutralising antibodies against antigenic sites
on the HA glycoprotein of the influenza virus (as assessed by HA
inhibition assay or microneutralisation assay) is regarded as the
criterion for evaluating immunity to influenza viruses and is
believed to constitute the main correlate of protection [5,6,7].
Although cell-mediated immunity also correlates with the rate of
viral clearance and protection of the respiratory tract after
challenge with infectious influenza viruses [8], cellular-mediated
immune responses have not been assessed following vaccination
with the A(H1N1)pdm/09 vaccines and only limited data is
available on the cellular-mediated immune responses elicited by
influenza vaccines in general [9].
Mice and ferrets are the most routinely used animal models for
the study of influenza infections and in particular for the
evaluation of human influenza vaccines [10,11]. In contrast, the
pig is not currently considered as a major experimental model for
influenza viruses, despite the fact that influenza viruses are
enzootic in pigs [12] and several studies show the pig as a valuable
model to study human influenza viruses: human influenza viruses
do replicate to a similar level in both the upper and lower
respiratory tract explants of pigs, which exhibit a similar sialic acid
receptor distribution and pattern of virus attachment to humans
[13,14], and infections of pigs with human influenza viruses under
natural conditions occur regularly [12]. Moreover, several studies
have now demonstrated in pigs the pathogenesis and transmission
of A(H1N1)pdm/09 influenza virus that emerged in 2009
[15,16,17]. In the present study, we assessed the immune
responses generated to intramuscular immunisation with two
commercial human influenza vaccines and challenge in inbred
large white pigs (Babraham line).
Materials and Methods
Ethics Statement
All experiments were approved by the ethical review processes
at the Institute for Animal Health (IAH) and Animal Health and
Veterinary Laboratories Agency (AHVLA), were in accordance
with national guidelines on animal use, and all efforts were made
to minimise suffering of animals.
Vaccines
Two commercial A(H1N1)pdm/09 influenza vaccines produced
from Cal07 were used in this study: an AS03b-adjuvanted split
virion vaccine (Pandemrix, GlaxoSmithKline Biologicals S.A.,
GSK, Rixensart, Belgium) and a non-adjuvanted whole virion
vaccine (Celvapan, Baxter AG, Vienna, Austria).
The adjuvanted split virion vaccine was manufactured from a
reassortant strain combining the HA, neuraminidase (NA) and
viral polymerase subunit (PB1) genes of Cal07 and the PR8 strain
backbone, generated by classical reassortment in embryonated
chicken eggs. This vaccine was supplied as a suspension (antigen)
and emulsion (adjuvant) multidose vial, and the volume after
mixing one vial of suspension (2.5 ml) with one vial of emulsion
(2.5 ml) corresponded to ten doses of vaccine. One dose (0.5 ml)
contained: (i) 3.75 mg HA antigen; (ii) the oil-in-water AS03
adjuvant composed of squalene (10.69 mg), DL-a-tocopherol
(11.86 mg) and polysorbate 80 (4.86 mg); and (iii) the excipient
thiomersal (5 mg). The vaccine vials were stored at 2–8uC and
used within 24 hours following mixing.
The non-adjuvanted whole virion vaccine was manufactured
from Cal07, grown in Vero cells and inactivated (formaldehyde
and UV irradiation). This vaccine was supplied as a 5 ml
multidose vial, corresponding to ten vaccine doses. One dose
(0.5 ml) contained 7.5 mg HA antigen. The vaccine vials were
stored at 2–8uC and used within 3 hours following opening of the
vial.
Study design
Inbred large white pigs (Babraham line) were conventionally
reared at the Institute for Animal Health (Compton, UK), with
ages ranging from three to four months and weighing 15–29 kg at
the initiation of the study. Prior to the study, all pigs were bled and
shown by ELISA to be negative for anti-influenza A virus
antibodies in the serum (i.e. not previously exposed to influenza A
viruses). The pigs (three animals per group) were intramuscularly
injected in the neck with one of the two commercial
A(H1N1)pdm/09 influenza vaccines mentioned above (0.5 ml
per pig). The vaccination regime was similar to that recommended
for adult humans: the adjuvanted split virion vaccine was
administered only once, whereas the whole virion vaccine was
administered twice (two doses three weeks apart). Another two pigs
were mock-vaccinated, i.e. received a single intramuscular
injection in the neck with 2.5 ml uninfected allantoic fluid
(corresponding to approximately 7.5 mg total egg protein) diluted
in a mixture of 0.25 ml PBS and 0.25 ml adjuvant (emulsion vial
from the adjuvanted split virion vaccine) per pig. Blood samples
were collected by anterior vena cava venepuncture at various
time-points following vaccination.
Three months after the initial vaccination, all pigs were
intranasally inoculated with 106 pfu of infectious A/England/
195/09 H1N1 (Eng195 - 106 pfu/4 ml – 2 ml per nostril), using a
mucosal atomisation device (MADH Nasal, Wolfe Tory Medical
Inc., Salt Lake City, UT) to mimic aerogenous infection that
results in the infection of both the upper and lower respiratory
tract [16]. This infectious virus strain was propagated in MDCK
cells. Clinical parameters (demeanour, respiratory signs, faeces
consistency and rectal temperature) were assessed and nasal swab
samples were collected one day before and every day after
challenge for 9 days. The swabs were stored in 1 ml RNAlater
(Applied Biosystems/Ambion, Austin, TX) and stored frozen at
280uC until tested by a modified influenza A M gene real-time
RT-PCR assay (RRT-PCR, as described below).
Culture medium
The culture medium was RPMI-1640 medium with glutamax-I
and 25 mM Hepes (Invitrogen Ltd., Paisley, UK) supplemented
with penicillin (100units/ml), streptomycin (100 mg/ml), 16 non-
essential amino acids, 1 mM sodium pyruvate and 10% heat-
inactivated pig serum (Invitrogen Ltd.), and was subsequently
termed complete medium. The commercial pig serum used in the
culture medium was checked to be negative for antibodies against
four swine influenza viruses mostly endemic in UK pigs (avian-like
H1N1[195852], classical H1N1, H1N2 and H3N2) and the
pandemic Eng195 (data not shown).
Immune Responses to A(H1N1)pdm/09 Vaccines in Pigs
PLoS ONE | www.plosone.org 2 March 2012 | Volume 7 | Issue 3 | e32400
Isolation and stimulation of pig peripheral blood
mononuclear cells (PBMC)
Blood (25–40 ml per pig) was collected in heparinised tubes at
various time-points post vaccination (i.e. day 0, 7, 12, 21, 28, 33,
93 and 100), and PBMC were obtained by density gradient
centrifugation (12006g for 30 min over HistopaqueH 1.083 g/ml,
Sigma-Aldrich, Poole, UK). 26105 PBMC per well were cultured
(10 replicates per condition) in U-shape 96-well microtiter plates in
200 ml complete medium alone or with the following stimuli:
105EID50/ml LBP-inactivated Cal07 (grown in embryonated
chicken eggs, corresponding to a 1/1000 dilution of virus stock),
105 pfu/ml UV-inactivated Eng195 (grown in MDCK cells,
corresponding to a 1/20 dilution of virus stock), mock antigen
(uninfected allantoic fluid diluted at 1/1000 or MDCK lysate
diluted at 1/20) or 1 mg/ml pokeweed mitogen (PWM, Sigma-
Aldrich). PBMCs were then incubated for 3 days at 37uC in a 5%
CO2 incubator, before harvesting cell supernatants to assess
interferon gamma (IFNc) production by ELISA or harvesting cells
to quantify IFNc-producing cells by ELISPOT.
For the assessment of cell proliferation, a number of PBMC
were labelled with carboxyfluorescein diacetate succinimydyl ester
(CFSE) cell tracer (Invitrogen Ltd) immediately after their
isolation. Briefly, PBMC (56106/ml in pre-warmed PBS) were
incubated with 0.5 mg/ml CFSE in a water bath for 15 min at
37uC. Cells were recovered by centrifugation, suspended at
56106cells/ml in pre-warmed complete medium and incubated
in a water bath for a further 30 min at 37uC. Subsequently, cells
were washed twice, suspended at the appropriate concentration
(26106cells/ml) in complete medium and stimulated for five days
as described above for unlabelled PBMC.
Swine IFNc ELISA
Swine IFNc was measured in cell supernatants of PBMC
cultured for 3 days (as described above) by using a commercial
ELISA kit (Thermo Scientific, Rockford, IL), according to the
manufacturer’s instructions. Concentrations of swine IFNc in test
samples were determined by extrapolation to the linear part of the
standard curve and taking into account any extra dilution factor
applied to the samples. Results were expressed as pg swine IFNc/
ml and the lower detection limit for the assay was 2 pg/ml.
Swine IFNc ELISPOT
MultiScreenTM-HA ELISPOT plates (Millipore, Watford, UK)
were coated for two hours at room temperature with 1 mg/ml
mouse anti-pig IFNc (BD Biosciences, San Jose, CA) in carbonate
buffer (0.1 M Na2CO3/NaHCO3, pH 9.6). Plates were washed
five times with PBS and subsequently incubated for two hours at
37uC with 100 ml per well of blocking buffer (PBS containing 4%
dried skimmed milk). Plates were then washed five times with PBS
and stored at 4uC until use.
For each culture condition, ten wells of 3 day-stimulated PBMC
(as described above) were pooled and resuspended in 200 ml
complete media (equivalent to 107 initial cells/ml) and 2-fold serial
dilutions were performed in complete medium down to 3.16105
cells/ml. 100 ml/well of each cell suspension was added to the
coated ELISPOT plates and cultured overnight at 37uC in a 5%
CO2 incubator. Cells were washed off the plates using PBS
containing 0.05% Tween20, then 100 ml per well biotinylated
mouse anti-pig IFNc (0.5 mg/ml, BD Biosciences) was added to
the plates for 2 hours at room temperature. Plates were washed
five times with PBS containing 0.05% Tween20 and 100 ml per
well streptavidin conjugated to alkaline phosphatase (1/1000,
Invitrogen Ltd.) was added to the plates for 1 hour at room
temperature. Plates were washed five times with PBS containing
0.05% Tween20 and 100 ml per well alkaline phosphatase
substrate solution (Biorad laboratories, Hercules, CA) was added
for 20 min at room temperature. Plates were then rinsed with tap
water and allowed to dry overnight at room temperature before
counting the dark blue-coloured immunospots using the AID
ELISPOT reader (AID Autoimmun Diagnostika GmbH, Strass-
berg, Germany). Results were expressed as IFNc-producing cell
number per 106 stimulated PBMC.
Assessment of cell proliferation in T cell subsets
For each culture condition, ten wells of 5 day-stimulated CFSE-
labelled PBMC (equivalent to 26106 initial cells) were pooled,
resuspended in 100 ml FACS buffer (PBS containing 1% bovine
serum albumin and 0.1% sodium azide) and analyzed by
immunofluorescence using the following reagents: biotinylated
mouse anti-porcine CD4 (clone MIL17, 1/300 of a monoclonal
antibody purified from hybridoma culture supernatant and
biotinylated at the IAH) and PE-conjugated mouse anti-porcine
CD8a (clone 76-2-11, BD Biosciences) monoclonal antibodies,
followed by incubation with APC-conjugated streptavidin (1/200,
Southern Biotechnology Associates, Birmingham, AL). 50,000
viable cells per sample were analyzed using a FACScan flow
cytometer (BD Biosciences).
Detection of influenza-specific antibodies by ELISA
Serum was collected at various time-points post vaccination (i.e.
day 0, 7, 12, 21, 28, 33, 93 and 100) for the assessment of
influenza-specific antibodies by ELISA. 96-well ELISA plates were
coated overnight at 4uC with pre-optimized concentrations of
Eng195 grown in embryonated chicken eggs (1 mg/ml). Threefold
dilutions of test sera and reference serum starting from 1/3 in
PBS-Tween plus egg powder (1 mg/ml, to competitively inhibit
any anti-egg antibody) were applied. Binding of antibodies was
detected with monoclonal antibodies specific for porcine IgG1
(K139.3C8, AbD Serotec, Kidlington, UK) and IgG2 (K68.1G2,
AbD Serotec), followed by goat anti-mouse IgG (Fc-specific)
conjugated to horseradish peroxidase (Sigma-Aldrich), all used at
optimal dilutions. Finally, ortho-phenylenediamine (OPD, Sigma-
Aldrich) in carbonate buffer was added and the optical density
values were read for each well at dual wavelengths (405 nm and
492 nm) using a Labsystems Multiskan plate reader (Fisher
Scientific, Loughborough, UK). The reference serum (obtained
at day 14 post-infection from a pig experimentally challenged with
106EID50 of infectious Eng195) was assigned arbitrary antibody
units (log 3) and serial dilutions were used to construct a standard
curve. The quantities of antibody in test sera were determined by
the interpolation of optical density values from all dilutions falling
within the reference range. All antibody values were expressed
relative to the standard as Log ELISA units (EU).
Detection of haemagglutination inhibition (HI) titres
Antibody titres were measured by use of a HI assay following
the protocol detailed thereafter. In brief, 100 ml serum samples
were pre-treated with 400 ml receptor destroying enzyme (RDE,
1/20 dilution in calcium saline solution, Sigma-Aldrich) at 37uC
overnight. 300 ml sodium citrate (3%) was added per sample and
incubated for a further 30 minutes at 56uC for enzyme
inactivation. The strain of influenza virus (Eng195) used in this
assay was grown in embryonated chicken eggs and inactivated by
treatment with beta-propiolactone. 25 ml (4 haemagglutination
units) of influenza virus was incubated at 37uC for one hour with
an equal volume of 2-fold serial dilutions of RDE-treated serum
starting from 1/8 in V-shape 96-well microtiter plates. 50 ml of 1%
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(vol/vol in PBS) chicken red blood cells was then added to each
well and incubated for 45 min at room temperature after gentle
mixing. Haemagglutination inhibition was read immediately after
the last incubation, and HI titers were expressed as the reciprocal
of the highest dilution of serum where haemagglutination was
prevented.
Matrix (M) gene RRT-PCR
Total RNA was extracted with the RNeasyH mini kit (Qiagen,
Crawley, UK) according to the manufacturer’s instructions with
minor modifications as described thereafter. Briefly, nasal swabs
were thawed, vortexed and 600 ml of the swab storage medium
(RNAlater) was clarified by centrifugation at 12,0006g for 10 min.
500 ml of the clarified supernatant was mixed with 1.5 ml RLT
buffer (containing ß-mercaptoethanol) and 2 ml 75% ethanol, and
applied to the RNeasy spin column. Subsequently, the kit protocol
for purification of total RNA from animal cells was followed and
total RNA was eluted in 30 ml RNase-free water.
The modified M gene RRT-PCR utilised the forward primer
and probe originally described by Spackman et al [18], with a
reverse primer modified to provide a perfect sequence match with
the novel pandemic H1N1 virus, typified by Cal07 (accession
number: FJ966975) [16]. The four altered nucleotides in the
modified reverse primer are indicated in upper case: 59-tgc aaa
Gac aCT ttc Cag tct ctg-39. The superscript III platinum one-step
quantitative RT-PCR kit (Invitrogen Ltd.) was used with a 25 ml
reaction mixture containing 0.5 ml of kit-supplied enzyme mixture
(including RT and hot-start Taq polymerase), 0.9 mM of each
primer, 0.4 mM probe, 12.5 ml 26reaction mix (including MgSO4
and dNTPs), 0.5 ml of 25 nM ROX reference dye and 3 ml total
RNA. RRT-PCR was performed with the 7500 Fast Real-Time
PCR system thermocycler and sequence detection software
(Applied Biosystems, Foster City, CA) as follows: (i) the RT step
conditions were 5 min at 50uC and 2 min at 95uC; and (ii) the
two-step PCR cycling protocol was 40 cycles of 95uC for 3 sec and
60uC for 30 sec. Fluorescence data were acquired at the end of
each annealing step.
RNA from 500 ml RNAlater containing ten-fold dilutions of a
titrated sample of MDCK-grown Eng195 (106 to 101 pfu) was
extracted in a similar manner as RNA from nasal swabs. This
served to calibrate the Ct values derived from testing extracted
clinical specimens by the modified M gene RRT-PCR with an
equivalent viral infectivity titre that is expressed in relative
equivalent units (REU) [19].
Statistical analysis
Time-course data (IFNc ELISA/ELISPOT, IgG1/IgG2/HI
titres, virus shedding and body temperature) were analysed using
linear mixed models with animal as a random effect and an
autoregressive, AR(1), correlation structure [20]. Where appropriate,
data were log transformed. Model selection proceeded by stepwise
deletion of non-significant terms (as judged by changes in the Akaike
information criterion), starting from an initial model including day
and vaccination as fixed effects and an interaction between these
factors. However, exploratory analyses indicated substantial depar-
tures from normality when using linear mixed models for both IFNc
ELISA and HI titres, even after transformation. Accordingly, these
data were analysed using Kruskal-Wallis tests to investigate the
impact of vaccination at individual time-points.
Proliferation data for each T cell subset (CD4+CD82,
CD4+CD8+ or CD42CD8+) were analysed using linear mixed
models. Model selection proceeded by stepwise deletion of non-
significant terms (as judged by changes in the Akaike information
criterion), starting from an initial model including treatment and
vaccination as fixed effects and an interaction between these
factors and animal as a random effect.
As a measure of the total amount of viral RNA detected, the
area-under-the-curve (AUC) was computed for each animal by
applying the trapezium rule to the viral RNA data. AUC was
compared between animals using a Kruskal-Wallis test.
All statistical modelling was carried out using the nlme package
in R (http://www.R-project.org/). P values equal to or below 0.05
were considered statistically significant.
Results
High Ab titres were generated following vaccination with
both the non-adjuvanted whole or adjuvanted split
A(H1N1)pdm/09 influenza vaccines
Influenza-specific IgG1 and IgG2 Ab titres were quantified by
ELISA using serum samples collected from each pig at various
Figure 1. Antibody titre after vaccination and challenge. Pigs
were vaccinated with the adjuvanted split (solide line), non-adjuvanted
whole (dashed line) or mock (dotted line) vaccine. The non-adjuvanted
whole vaccine was administered twice (at day 0 and day 21pv). At day
93pv, all pigs were challenged with Eng195. Serum samples were taken
at various time-points post-vaccination and challenge, and IgG1 (A) and
IgG2 (B) Ab titres were quantified by ELISA. Results are expressed as the
mean Log EU value 6 SEM. *, P,0.05.
doi:10.1371/journal.pone.0032400.g001
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time points post-vaccination (pv). Both vaccines induced a
significant systemic Ab response, which was predominantly of
the IgG1 isotype (Figure 1A and 1B). Indeed, IgG1 titres were
increased from 22.8860.04LogEU at day 0pv to 20.5360.15Lo-
gEU at day 33pv in pigs vaccinated with the adjuvanted split
vaccine, whereas IgG2 titres only rose from 23.3460.03LogEU at
day 0pv to 21.7560.21LogEU at day 33pv (n = 3). Similar results
were obtained in pigs vaccinated with the non-adjuvanted whole
vaccine. Moreover, pigs vaccinated with the adjuvanted split
vaccine produced significantly more specific IgG1 antibodies after
one vaccination, compared to those vaccinated with the non-
adjuvanted whole vaccine (20.6160.14LogEU versus
22.3360.09LogEU at day 21pv, respectively, P,0.05, n = 3).
IgG1 Ab titres in pigs vaccinated with the non-adjuvanted whole
vaccine were however boosted after the second vaccination, and
finally reached high titres by day 33pv (21.3460.16LogEU,
n = 3). Nevertheless, IgG1 titres were significantly higher for
animals vaccinated with the adjuvanted split vaccine compared to
those vaccinated with the non-adjuvanted whole vaccine from day
12pv to day 93pv (P,0.05, n = 3). Noticeably, both IgG1 and
IgG2 Ab titres were significantly increased following intranasal
challenge with infectious Eng195 influenza virus in all pigs
vaccinated with the A(H1N1)pdm/09 influenza vaccines. At day
100pv (i.e. day 7 post-challenge), IgG1 and IgG2 Ab titres
respectively reached 20.2960.11LogEU and 20.3360.12LogEU
for pigs vaccinated with the non-adjuvanted whole vaccine, and
0.2060.23LogEU and 0.1460.18LogEU for pigs vaccinated with
the adjuvanted split vaccine (n = 3). In contrast, influenza-specific
IgG1 and IgG2 Ab titres were not increased in mock-vaccinated
pigs at day 100pv, and it is likely this time-point was too early for
their detection as high levels of Ab would only be expected from
day 12–14 post-challenge in these naı¨ve animals.
Since HI titres are considered correlates of protection against a
subsequent challenge with infectious influenza virus, we also
determined HI titres in the serum samples collected from each pig
during the course of our study (Table 1). Similarly to the IgG1 titres,
HI titres were significantly increased in pigs vaccinated with the
adjuvanted split vaccine after only one injection (reaching 107621 at
day 28pv, P = 0.04, n = 3). Although undetectable in pigs vaccinated
with the non-adjuvanted whole vaccine after the first injection, HI
titres were also significantly increased after the second vaccine
injection (reaching 53611 at day 28pv, P = 0.05, n = 3). Following
challenge, HI titres were significantly higher in pigs vaccinated with
the non-adjuvanted whole vaccine or adjuvanted split vaccine as
compared to mock-vaccinated pigs, reaching 1,3656341,
2,7306682 and 192664, respectively, at day 100pv (P = 0.05, n = 3).
IFNc response was elevated only following vaccination
with the adjuvanted split vaccine
A small but significant amount of IFNc was detected only in
PBMC isolated from pigs vaccinated with the adjuvanted split
vaccine at day 7pv cultured in vitro in the presence of inactivated
Cal07 for 3 days (1263 pg/ml, P = 0.05, n = 3) (Figure 2A).
Indeed, no influenza-driven IFNc was detected in the supernatants
of PBMC from pigs vaccinated with the adjuvanted split vaccine
isolated at any other day following the vaccination, or at any time-
point from pigs vaccinated with either the non-adjuvanted whole
vaccine or mock-vaccine (P.0.1, n = 3). Moreover, IFNc
production was not detected in the supernatant of PBMC isolated
from any of the pigs, when cultured in the presence of mock
antigen (egg allantoic fluid) or media only (data not shown).
Using in vitro culture conditions similar to those described above
for the IFNc ELISA, we also quantified the number of IFNc-
producing cells in pig PBMC stimulated for three days with
inactivated Cal07 by ELISPOT. We detected a significant amount
of influenza-driven IFNc-producing cells in PBMC isolated from
pigs vaccinated with the adjuvanted split vaccine, which peaked at
day 7pv (46620 pg/ml, adjusted P,0.01, n = 3) and subsequently
remained at a low level until day 28pv (Figure 2B). In contrast,
no influenza-driven IFNc-producing cells were detected in PBMC
from pigs vaccinated with the non-adjuvanted whole vaccine or
mock-vaccine at any time-point (adjusted P = 0.99, n = 3).
Similarly, IFNc-producing cells were not detected in PBMC
isolated from any of the pigs, when cultured in the presence of
mock antigen (egg allantoic fluid) or media only (data not shown).
Influenza-specific recall proliferative responses were
detected in various T cell sub-populations of vaccinated
pigs
Several T cell subsets in pigs have been identified on the basis of
CD4 and CD8 cell surface expression, and are generally defined as
Table 1. HI titres after vaccination and challenge.
HI titresa
Mock Non-adjuv. whole Adjuv. split
Days post-vaccination Pig #4 Pig #8 Pig #5 Pig #6 Pig #7 Pig #1 Pig #2 Pig #3
0b ,8 ,8 ,8 ,8 ,8 ,8 ,8 ,8
7 ,8 ,8 ,8 ,8 8 ,8 ,8 8
12 ,8 ,8 ,8 ,8 ,8 32 ,8 16
21c ,8 ,8 ,8 ,8 ,8 64 128 128
28 ,8 ,8 64 32 64 64 128 128
33 ,8 ,8 64 32 32 64 128 128
93d ,8 ,8 ,8 16 ,8 ,8 32 128
100 256 128 1024 2048 1024 4096 2048 2048
a: HI titres were determined using 4 HA unit per well of inactivated A/England/195/09 H1N1 influenza virus.
b: Day of vaccination (all pigs).
c: Day of boost vaccination (only pigs vaccinated with the non-adjuvanted whole vaccine).
d: Day of challenge (all pigs).
doi:10.1371/journal.pone.0032400.t001
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follows: naı¨ve/non-activated CD4+CD82 T cells, cytotoxic
CD42CD8+ T cells (CTL) and memory/activated CD4+CD8+
T cells (Thelper) [21,22]. Here, we assessed the level of proliferation
(determined as the percentage of CFSElow cells) in each of these T
cell subsets within pig PBMC following their in vitro culture in the
presence of inactivated Eng195 for 5 days (Figure 3A). A
significant influenza-driven recall response was generated in pigs
vaccinated with the adjuvanted split vaccine in the CD4+CD82,
CD4+CD8+ and CD42CD8+ subsets (461%, 1664% and
1261% CFSElow cells, respectively, P,0.05, n = 3, Figure 3B–
D). In contrast, a significant influenza-driven recall response was
only generated in the CD4+CD8+ subset (661% CFSElow cells,
P,0.01, n = 3), but not in the CD4+CD82 and CD42CD8+
subsets (160% and 260.3% CFSElow cells, P.0.94, n = 3), in pigs
vaccinated with the non-adjuvanted whole vaccine (Figure 3B–
D). For each T cell subset, PWM was used as a positive control
and induced comparable levels of proliferation in all groups of
pigs, irrespective of their vaccination regime (Figure 3B–D).
Similar results were obtained when using PBMC isolated on the
day of challenge (day 93pv, data not shown). This suggests the
non-adjuvanted whole vaccine only generated a Thelper cell
response, whereas the adjuvanted split vaccine elicited a Thelper
cell response associated with a CTL response.
Similar levels of viral RNA were detected from the nasal
cavity of pandemic- and mock-vaccinated pigs after
challenge with Eng195 influenza virus
Three months after the initial vaccination (day 93pv), all pigs
were challenged intra-nasally with 106 pfu of infectious Eng195
influenza virus. No or very mild clinical signs were observed in all
pigs following this infectious challenge. Indeed, these clinical signs
were: one animal in the group vaccinated with the adjuvanted split
vaccine exhibited sneezing at day 2 post-challenge (pc) and one
animal in the mock-vaccinated group showed some nasal
discharge at days 6pc and 7pc (data not shown). Rectal
temperatures were slightly elevated only at day 2pc in all pigs as
follows: pigs vaccinated with the non-adjuvanted whole vaccine
(from 38.760.2uC before challenge to 39.860.5uC at day 2pc,
adjusted P,0.01, n = 3), pigs vaccinated with the adjuvanted split
vaccine (from 38.360.2uC before challenge to 39.560.2uC at day
2pc, adjusted P,0.01, n = 3) and mock-vaccinated pigs (from
38.960.2uC before challenge to 39.960.6uC at day 2pc, adjusted
P,0.01, n = 2) (Figure 4A).
Levels of viral RNA (indicative of shed virus) in nasal swabs
taken at various time-points post-challenge were determined using
a modified influenza A matrix gene RRT-PCR assay and were
expressed in REU as described in materials and methods. Our
results showed that similar patterns of viral RNA detected in the
upper respiratory tract were observed in all pandemic- and mock-
vaccinated pigs (Figure 4B). Indeed, all shedding curves were
biphasic with a first peak of nasal shedding occurring at day 2pc
(32,24064,180 REU, 33,6226969 REU and 205,2336154,813
REU for pigs vaccinated with the mock vaccine, the non-
adjuvanted whole vaccine and the adjuvanted split vaccine,
respectively) and a second peak at day 4pc (10,79261,561 REU,
9,62768,703 REU and 1,2716882 REU for pigs vaccinated with
the mock vaccine, the non-adjuvanted whole vaccine and the
adjuvanted split vaccine, respectively), followed by a gradual
decrease thereafter. Overall, there were no significant differences
(P.0.25) in the levels of viral RNA detected between animals
receiving different vaccines at any time point post challenge.
Furthermore, there were no significant differences between
animals in the total amount of viral RNA detected (i.e. area-
under-the-curve, AUC) regardless of the vaccine received
(P = 0.76).
Discussion
In this study, we assessed the cellular and humoral immune
responses generated following the vaccination of Babraham pigs
with two human A(H1N1)pdm/09 influenza vaccines that were
used for the national human immunisation programme in the UK.
The choice of using the pig as a model in the present study was
based on the following: (i) Swine influenza viruses are enzootic in
pigs, with classical swine H1N1, ‘‘avian-like’’ H1N1, ‘‘human-like’’
H1N2 and ‘‘human-’’ and ‘‘avian-like’’ H3N2 subtypes of
influenza A being reported world-wide in pig populations [12];
(ii) Human and swine influenza viruses replicate to similar levels in
Figure 2. Interferon gamma response after vaccination and
challenge. Pigs were vaccinated with the adjuvanted split (solid line),
non-adjuvanted whole (dashed line) or mock (dotted line) vaccine. The
non-adjuvanted whole vaccine was administered twice (at day 0 and
day 21pv). At day 93pv, all pigs were challenged with Eng195. Blood
samples were taken at various time-points post-vaccination and
challenge. 26105 PBMC per well were cultured in vitro for 3 days in
the presence of 105EID50/ml inactivated Cal07, and interferon gamma
(IFNc) production was quantified in the supernatants by ELISA (A) and
IFNc-producing cells were quantified in the cellular fraction by ELISPOT
(B). Results are expressed as the mean pg/ml (A) and IFNc-producing
cells per 106 stimulated PBMC (B) 6 SEM. *, P = 0.05. **, P equal to or
below 0.01.
doi:10.1371/journal.pone.0032400.g002
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the upper and lower respiratory tract of pigs with a similar viral
shedding pattern [13,16,17,23] and (iii) The pig respiratory tract
exhibits a distribution of sialic acid (Sia) with a2-6 (Siaa2-6Gal,
preferred receptor for human influenza virus) and a2,3 (Siaa2-
3Gal, preferred receptor for avian influenza virus) linkages to
galactose and a pattern of virus attachment similar to humans
[13,14]. Moreover, the Babraham inbred pigs are particularly
valuable for performing immunological studies since these pigs are
85% identical as assessed by genome-wide SNP analysis (Alan
Archibald, personal communication) and are matched for MHC
type I and type II molecules [24]. Therefore, the genetic similarity
between individual Babraham pigs also justifies the use of a lower
number of animals per group (as compared to studies using
outbred pigs), while allowing the assessment and dissection of the
immune response in greater detail.
The influenza-specific Ab responses in the serum of vaccinated
pigs were dominated by the IgG1 isotype. Such a bias towards an
IgG1-dominated response has previously been demonstrated in
pigs immunised with other antigens, e.g. ovalbumin or foot-and-
mouth disease virus subunit [25,26]. Pigs vaccinated with the
Figure 3. T cell sub-population proliferation monitored by CFSE labelling in response to in vitro re-stimulation with H1N1 influenza.
CFSE-labelled PBMC were cultured in vitro in the presence of 105EID50/ml inactivated Eng195, uninfected allantoic fluid (mock antigen), PWM or in
media only. After 5 days, cells were stained with anti-CD4 and anti-CD8 monoclonal antibodies and analysed by flow cytometry for CFSE intensity.
Three T cell subsets were identified on the basis of their CD4 and CD8 expression, and an example of the CFSE pattern at day 7pv in response to
inactivated Eng195 in these various subsets in a pig vaccinated with the adjuvanted split vaccine is shown (A). At day 28pv, the percentage of cells
proliferating (CFSELow cells) in response to media alone, mock antigen or inactivated Eng195 was determined after gating on CD4
+CD82 (B),
CD4+CD8+ (C) or CD42CD8+ (D) cells. Results are expressed as the mean percentage of proliferating (CFSELow) cells 6 SEM. n.s =Not statistically
significant.
doi:10.1371/journal.pone.0032400.g003
Immune Responses to A(H1N1)pdm/09 Vaccines in Pigs
PLoS ONE | www.plosone.org 7 March 2012 | Volume 7 | Issue 3 | e32400
adjuvanted split vaccine exhibited a significantly higher IgG1
response after one vaccination as compared to pigs vaccinated
with the non-adjuvanted whole vaccine. However, IgG1 titres in
the latter pigs were boosted after the second vaccination, and
finally reached high titres (although significantly lower than those
in pigs vaccinated with the adjuvanted split vaccine). Interestingly,
both influenza-specific IgG1 and IgG2 titres increased following
challenge with Eng195 influenza virus. This suggests that the
A(H1N1)pdm/09 vaccines assessed in this study mostly generated
influenza-specific IgG1 antibodies, in contrast to infection with live
virus that generated a more balanced and broader immune
response. Pigs vaccinated with the adjuvanted split vaccine also
generated significantly higher HI titres after one vaccination, and
pigs vaccinated with the non-adjuvanted whole vaccine showed a
good HI response only after the boost vaccination (although lower
than that observed in pigs vaccinated with the adjuvanted split
vaccine). Very little data is available on the duration of neutralising
antibody responses in human subjects vaccinated with these two
commercial A(H1N1)pdm/09 vaccines. Recently, Madhun et al.
[4] reported that health care workers vaccinated with the
adjuvanted split vaccine exhibited high HI titres 21 days after
the vaccination (geometric mean titre = 473.5) that were decreased
three months later (geometric mean titre = 232.2). Based on this
report, HI titres in human subjects were slightly higher than in pigs
vaccinated with the adjuvanted split vaccine, and were slightly
decreased in both species two to three months later. In another
report, Waddington et al. [5] showed that HI titres in children
vaccinated with the non-adjuvanted whole vaccine ranged from
60.3 to 79.6 at day 21 after the second vaccination, which is
comparable to the HI values observed in pigs at day 12 after the
second vaccination in our study (range 32–64). Nevertheless,
duration of neutralising antibody responses could not be compared
between pigs and humans from this report since the authors did
not assess HI titres in these children at later time-points. HI values
in children vaccinated with the adjuvanted split vaccine could not
be compared since these children did not receive one but two
injections of the vaccine.
In response to in vitro stimulation of PBMC with inactivated
H1N1 influenza virus, we detected a peak of IFNc-producing cells
and IFNc production at day 7pv, but only in pigs vaccinated with
the adjuvanted split vaccine. Such an anamnestic response in the
number of influenza-specific IFNc-producing cells in the blood has
similarly been detected only at day 7 after the challenge of pigs
with A/Sw/Indiana/1726/88 H1N1 swine influenza virus [27].
The authors of this study further showed this response was
enhanced and detectable for a longer period of time (up to day 21
post-challenge) in the spleen, tracheobronchial lymph nodes and
nasal mucosa [27]. Using CFSE labelling and flow cytometry, we
determined the identity of the T cell subsets with the capacity to
proliferate in response to an in vitro re-stimulation with inactivated
H1N1 influenza virus. In addition to the classical CD4+CD82 and
CD42CD8+ T cell subsets, pig PBMCs are also known to contain
a substantial number of CD4+CD8+ T lymphocytes. Importantly,
these CD4+CD8+ T cells express CD8aa (not CD8ab) molecule,
are major histocompatibility complex (MHC) class II-restricted
and are generally considered as memory/activated Thelper cells
[21,22]. Our results demonstrated an influenza-specific recall
response in the CD4+CD82 (naı¨ve), the CD42CD8+ (CTL) and
the CD4+CD8+ (Thelper) cells of pigs vaccinated with the
adjuvanted split vaccine, but only in the CD4+CD8+ (Thelper) cells
of pigs vaccinated with the non-adjuvanted whole vaccine. It is
tempting to speculate that the lack of IFNc response observed in
pigs vaccinated with the non-adjuvanted whole vaccine (even
following the boost vaccination) may reflect the incapacity or at
least the low efficiency of the non-adjuvanted whole vaccine to
elicit an influenza-specific CTL response in these pigs. These killed
vaccines are likely to stimulate CTL responses by cross-priming. It
has been previously shown that some adjuvants have the ability to
strongly enhance antigen cross-presentation (including that of
peptide or protein antigen) [28,29,30]. AS03 adjuvant contained
in the adjuvanted split vaccine is known to induce local
inflammation and recruitment of various innate immune cells
[31], and may similarly enhance antigen cross-presentation.
Despite the fact that both vaccines elicited systemic humoral
responses and one of these (adjuvanted split vaccine) also elicited
an enhanced cell-mediated immune response, none of the pigs
Figure 4. Body temperature and detection of viral RNA in the
nasal cavity after infectious challenge. Pigs were vaccinated with
the adjuvanted split (solid line), non-adjuvanted whole (dashed line) or
mock (dotted line) vaccine, and all pigs were subsequently challenged
with infectious Eng195 influenza virus. (A) Rectal temperature (in uC)
was monitored one day prior and everyday following challenge. Results
are expressed as the mean value 6 SEM for each vaccination group.
*, P,0.01. (B) Nasal swabs were collected one day prior and everyday
following challenge. Shedding was measured in all samples through the
detection of viral RNA by a modified influenza A M gene real-time RT-
PCR (RRT-PCR) assay. By the use of a standard curve (on each test plate)
generated from a dilution series of infectious Eng195 virus, the relative
equivalent unit (REU) of viral RNA was determined based upon the cycle
threshold (Ct) value obtained for each sample. Results are expressed as
the mean REU 6 SEM for each vaccination group.
doi:10.1371/journal.pone.0032400.g004
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were protected from a subsequent virus challenge at 3 months
post-vaccination as viral RNA continued to be detected in the
nasal cavity. Interestingly, although it has previously been shown
that pigs with an HI titre equal to or above 20 were generally
protected from a subsequent influenza challenge [32], two out of
the three pigs vaccinated with the adjuvanted split vaccine still
exhibited HI titres equal to or above 32 at the time of challenge
but were nevertheless not protected. It is still unclear how the
systemic responses generated after vaccination correlate with local
mucosal responses in the respiratory tract [10] that may also
contribute to reduction in virus shedding. Interestingly, a similar
study was conducted in ferrets, challenged six weeks after the
initial vaccination, by the pandemic influenza vaccine evaluation
consortium (PIVEC) that generated results consistent with our
own findings. This study showed the A(H1N1)pdm/09 vaccines
reduced (adjuvanted split vaccine) or had no effect on (non-
adjuvanted whole vaccine) the viral shedding from the upper
respiratory tract, although the adjuvanted split vaccine did prevent
viral replication in the lower respiratory tract of ferrets [33].
In conclusion, the present study provides support for the use of
the pig as a valid experimental model for influenza infections in
humans, including the assessment of protective efficacy of
therapeutic interventions. This animal model offers improvements
over that of mice and ferrets with clinical, pathological and
immune responses similar to those induced in humans, and
therefore has potential wide utility. The growing number of
reagents to study the cell surface phenotype and function of
immune cells in the pig will help dissect local and systemic
responses. Moreover, the use of the inbred pig line will facilitate
these investigations by allowing cell transfer studies and MHC I
and II tetramer analysis.
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